CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers

被引：0
|
作者：
Slade, A. [1 ]
Doucet, J. [2 ]
Koo, P. [1 ]
Espie, P. [2 ]
Rush, J. [2 ]
Tomek, C. [3 ]
Klupp, J. [2 ]
机构：
[1] Novartis Inst Biomed Res, E Hanover, NJ USA
[2] Novartis Inst Biomed Res, Basel, Switzerland
[3] Celerion Inc, Lincoln, NE USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2015年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
2007
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patient and investigator reported outcomes suggest improvements upon treatment with the novel anti-CD40 monoclonal antibody CFZ533 in patients with primary Sjogren's syndrome: a phase iia double-blind, placebo-controlled randomized trial
    Papas, Athena S.
    Farag, Arwa M.
    Fisher, Benjamin
    Zeher, Margit
    Ng, Wan-Fai
    Bombardieri, Michele
    Posch, Maximilian
    Daikeler, Thomas
    Bannert, Bettina
    Kivitz, Alan J.
    Carsons, Steven E.
    Isenberg, David A.
    Barone, Francesca
    Bowman, Simon
    Espie, Pascal
    Wieczorek, Grazyna
    Moulin, Pierre
    Floch, David
    Dupuy, Cyrielle
    Ren, Xiaohui
    Faerber, Petra
    Wright, Andrew M.
    Hockey, Hans Ulrich
    Rotte, Michael
    Rush, James S.
    Gergely, Peter
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : S251 - S252
  • [22] Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy
    Bruhns, Pierre
    Teillaud, Jean-Luc
    CANCER CELL, 2016, 29 (06) : 771 - 773
  • [23] Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
    Fredrik N. Albach
    Frank Wagner
    Andreas Hüser
    Julia Igel
    David Joseph
    James Hilbert
    Corinna Schoelch
    Steven J. Padula
    Jürgen Steffgen
    European Journal of Clinical Pharmacology, 2018, 74 : 161 - 169
  • [24] Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
    Albach, Fredrik N.
    Wagner, Frank
    Hueser, Andreas
    Igel, Julia
    Joseph, David
    Hilbert, James
    Schoelch, Corinna
    Padula, Steven J.
    Steffgen, Jeurgen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (02) : 161 - 169
  • [25] Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers
    Kim, Jiyoon
    Tsuda, Yasuhiro
    Yamamoto, Kazuhiko
    Thiedmann, Ralf
    Schoelch, Corinna
    Norris, Stephen
    Padula, Steven
    Steffgen, Juergen
    Jang, In-Jin
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [26] Novel anti-CD40 antibodies demonstrate anti -tumor activity in humanized mouse models
    Guo, Chaoshe
    Yang, Benny
    Ni, Jian
    Guo, Yanan
    Gan, Tian
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb
    Morio, T
    Hanissian, SH
    Bacharier, LB
    Teraoka, H
    Nonoyama, S
    Seki, M
    Kondo, J
    Nakano, H
    Lee, SK
    Geha, RS
    Yata, J
    IMMUNITY, 1999, 11 (03) : 339 - 348
  • [28] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS
    Schwabe, C.
    Wagner, F.
    Filler, I.
    Albulescu, M.
    Rose, P.
    Emerson, B.
    Doan, T.
    Rosenstock, B.
    Joseph, D.
    Hilbert, J.
    Scholch, C.
    Habeck, J.
    Thiedmann, R.
    Padula, S.
    Steffgen, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 484 - 484
  • [29] AN ASSESSMENT OF THE SYSTEMIC ACTIVITY OF SINGLE DOSES OF INHALED FLUTICASONE PROPIONATE IN HEALTHY-VOLUNTEERS
    GRAHNEN, A
    ECKERNAS, SA
    BRUNDIN, RM
    LINGANDERSSON, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (06) : 521 - 525
  • [30] OM11-62MF: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Novel Anti-CD40 Antibody in Healthy Volunteers.
    Slade, A.
    Koo, P.
    Espie, P.
    Tomek, C.
    Rush, J.
    Klupp, J.
    Lee, D.
    TRANSPLANTATION, 2014, 98 : 115 - 115
12345